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REVIEW
Abstract: Peripheral arterial disease (PAD), like coronary heart disease, is a clinical
manifestation of atherosclerosis and is associated with increased mortality. Although
atherosclerotic cardiovascular disease is the leading cause of death for women as well as for
men, PAD in women has received less attention than coronary heart disease or stroke. This
paper reviews the prevalence of PAD, its risk factors, clinical significance, and management
in women. One gender-specific therapeutic issue of particular interest to practitioners and the
lay public is the role of postmenopausal hormone therapy. Prior to completion of the Heart
and Estrogen/Progestin Replacement Study and the Women’s Health Initiative Hormone Trials,
postmenopausal hormone therapy was believed to exert antiatherosclerotic effects and to
thereby reduce coronary heart disease risk in women on the basis of case-control and cohort
studies. This review particularly focuses on the role, if any, of postmenopausal hormone therapy
for prevention or treatment of PAD, which was a pre-specified secondary outcome for these
three randomized trials.
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Introduction
Atherosclerotic peripheral arterial disease (PAD) can be categorized as aortic or
involving arterial beds supplying the lower extremities, upper extremities, brain, or
viscera such as the kidneys or intestine. This review will focus on lower extremity
disease in women with particular focus on the role of postmenopausal hormone
therapy.
Diagnosis
The prevalence of PAD varies with its definition and with approaches to screening.
Clinical diagnosis of PAD is traditionally made by history of claudication or absent
or diminished pulses. The Rose questionnaire (Rose et al 1982), which has been
widely used to screen for claudication, will not detect asymptomatic disease. The
ratio of ankle systolic blood pressure to arm systolic blood pressure at rest, the so-
called ankle-brachial index, is an inexpensive approach to screening for asymptomatic
PAD (Table 1) and can be accurately conducted in the primary care setting (Raines et
al 2004). An ankle-brachial index of ≤ 0.90 has been reported to have 90% sensitivity
and 98% specificity for arterial stenosis ≥ 50% (Greenland et al 2000).
In the Rotterdam Study, 36 (5%) of 742 women with ankle-brachial index < 0.9
reported claudication on the Rose questionnaire (Meijer et al 1998). Symptoms of
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claudication were reported by a slightly higher proportion
of men with ankle-brachial index < 0.9, 37 of 424 (9%).
Claudication was reported by few women (15/3023, 0.5%)
or men (18/2135, 0.8%) with normal ankle-brachial indices.
Thus, reliance on claudication symptoms as a screening
approach for detection of PAD provides high specificity,
but poor sensitivity. Ankle-brachial index provides excellent
overall diagnostic accuracy without incurring the expense
associated with imaging studies such as ultrasound or
magnetic resonance angiography (Greenland et al 2000).
Nonetheless, the procedure is not reimbursed by many third-
party payers, including Medicare in the United States.
American Diabetes Association guidelines for preventive
foot care include a recommendation that ankle-brachial
index be considered in all patients with type 2 diabetes
(American Diabetes Association 2004). The Society of
Interventional Radiology recommends ankle-brachial index
measurement in all individuals being evaluated for PAD,
with a reminder that patients with diabetes may have heavily
calcified vessels, artificially elevating ankle pressure (Sacks
2003). In that setting, toe pressure determinations may more
accurately reflect peripheral perfusion.
Prevalence
The prevalence of PAD depends upon the characteristics of
the population studied and the definition of PAD used. The
Framingham Offspring Study defined PAD as ankle-brachial
index < 0.9 and identified it in 3.9% of 1554 men and 3.3%
of 1759 women in their predominantly white cohort
(Murabito 2002).
A recent assessment of PAD prevalence was conducted
by the National Health and Nutrition Examination Survey
(NHANES), which measured ankle-brachial index in a
probability sample of 2381 United States residents over
the age of 40 years from 1999–2000 (Gregg 2004).
Oversampling of the elderly, low-income persons, non-
Hispanic blacks, and Mexican Americans was undertaken
to permit more reliable estimates in these subpopulations.
In NHANES, the prevalence of PAD, defined as ankle-
brachial index < 0.90 in either leg, was 4.3% (95%
confidence interval [CI] 3.1%–5.5%). Peripheral arterial
disease was identified with similar frequency in men (4.5%,
95% CI 2.8%–5.6%) and women (4.2%, 95% CI 2.9%–
6.1%) and increased with age. Extrapolating from the
random NHANES sample to the United States’ population,
approximately 5 million adults, half of them women, have
abnormal ankle-brachial indices.
Clinical significance of peripheral
arterial disease
Both symptomatic and asymptomatic PAD predict
functional decline (McDermott 2004). Annual decline in
6-minute walk performance was more marked among
asymptomatic patients with ankle-brachial index < 0.9
(–77 feet, 95% CI –135 to –19 feet) than among healthy
Table 1 Measuring ankle-brachial index
The patient should lie supine for 5 minutes in a comfortable room and
position.
Measure brachial pressure
1. Place an appropriate sized blood pressure cuff (Table 2) above the
elbow; apply ultrasound gel over brachial artery.
2. Move the vascular Doppler ultrasound probe across the brachial
area until the arterial sound is identified; adjust probe to obtain
loudest signal. Steady your hand on the patient.
3. While maintaining this position, inflate the blood pressure cuff until
10–20 mmHg above the point where arterial flow is no longer
audible. Slowly deflate the cuff; the pressure at which the arterial
sound returns is the brachial pressure. Repeat for the other arm.
Measure ankle pressure
1. In general, posterior tibial pressure is preferred to dorsalis pedis
pressure. If values for both sites are obtained, use the highest value
to calculate the index.
2. Place appropriate size blood pressure cuff just above the ankle. For
the posterior tibial pressure, apply ultrasound gel behind the ankle
bone (medial malleolus). Abduct the foot to make the medial ankle
more accessible. Slowly scan behind the ankle bone until the arterial
sound is identified; adjust probe to obtain loudest signal. Steady your
hand on the patient.
3. For the dorsalis pedis pressure, position the probe on top of the
foot, halfway between the tips of toes and ankle, between the big toe
and second toe. Press lightly, as pressure may occlude the artery.
Once you identify the arterial sound, adjust probe position to find
the loudest signal.
4. While maintaining this position, inflate the blood pressure cuff until
10–20 mmHg above the point where arterial flow is no longer
audible. Slowly deflate the cuff; the pressure at which the arterial
sound returns is the ankle pressure. Repeat for the other ankle.
Calculate ankle-brachial index
Left ankle-brachial index = highest left ankle pressure ÷ highest brachial
pressure
Right ankle-brachial index = highest right ankle pressure ÷ highest
brachial pressure
Table 2 Choosing the appropriate blood pressure cuff size
(Perloff 1993)
Limb circumference
Cm Inches Cuff size
27–34 ≤ 13.4 Standard adult
35–44 13.7–17.3 Large adult
45–52 17.7–20.4 Adult thigh cuff
NOTE: An extra-large (XL) cuff is available for limbs 17–26 inches in
circumference, and extra-extra-large (XXL) for those 26–35 inches in
circumference (see www.amplestuff.com).Vascular Health and Risk Management 2005:1(2) 113
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controls (–9 feet, 95% CI –37 to +20 feet; p = 0.04). Annual
decline was even greater among patients with abnormal
ankle-brachial index and claudication (–111 feet, 95% CI
–173 to –50 feet; p = 0.004).
A small minority of patients with PAD will develop
critical leg ischemia over 5 years (~5%), with 1%–4%
progressing to amputation (Faxon 2004). In addition to the
impact of lower extremity atherosclerosis on downstream
tissue, PAD may be considered a general marker of
atherosclerosis; angiographic coronary disease is identified
in about 85%; and carotid stenosis, defined as > 30% by
ultrasonography, is identified in about 60% of patients with
PAD (Faxon 2004).
The presence of PAD has prognostic significance both
for coronary heart disease and death (Criqui 1992; Hooi
2004). Criqui et al (1992) followed 565 men and women
prospectively for 10 years. Among the 33 women with PAD
identified by either ankle-brachial index or Doppler
ultrasound, 33% died during follow up, compared with 26
of 225 (12%) of women without PAD. After multivariate
adjustment, the relative risk for all-cause mortality was 3.1
(95% CI 1.9–4.9) for individuals with prevalent PAD.
Relative risk for coronary death was 6.6 (95% CI 2.9–14.9).
The relationship between low ankle-brachial index and
cardiovascular disease was confirmed in the Cardiovascular
Health Study, a population-based cohort that included 3282
women aged ≥ 65 years (Newman 1999). Among individuals
without prevalent cardiovascular disease at baseline, the
hazard ratio in multivariate-adjusted Cox proportional
hazards models was 1.40 (95% CI 0.90–2.17) for myocardial
infarction, 1.12 (95% CI 0.74–1.70) for stroke, and 2.03
(95% CI 1.22–3.37) for cardiovascular death (Newman
1999).
The stroke risk with low ankle-brachial index was
stronger in the Framingham Heart Study, in an analysis
carried out when study participants’ mean age was 80 years
(Murabito 2003). In multivariate-adjusted Cox proportional
hazards analysis, the hazard ratio for stroke was 2.0 (95%
CI 1.1–2.7) among individuals with ankle-brachial index
< 0.9. The incidence of stroke was about 1.7% per year in
this analysis, compared with 0.6% per year in the
Cardiovascular Health Study (Newman 1999).
The relationship between ankle-brachial index and stroke
was also examined in the Atherosclerosis Risk in
Communities Study, which included 2450 black and 5776
white women, aged 45–64 years (Tsai 2001). The incidence
of stroke was low among women in this middle-aged cohort,
0.2% per year. In Cox proportional hazards analysis adjusted
for age, race, gender, center, blood pressure, diabetes,
smoking, cholesterol, and prevalent coronary heart disease,
ankle-brachial index did predict stroke risk (p-value for
trend 0.03).
Thus, epidemiologic data from a variety of cohort studies
strongly supports the relationship between low ankle-
brachial index and increased risk of myocardial infarction,
stroke, and death.
Peripheral arterial disease risk
factors
Risk factors associated with PAD are similar to those of
other atherosclerotic diseases. In NHANES, multivariate-
adjusted logistic regression models identified current
smoking as the strongest predictor of abnormal ankle-
brachial index (odds ratio [OR] 4.23, 95% CI 1.95–9.17)
(Gregg 2004). Other independent predictors of PAD
included diabetes mellitus (OR 2.08, 95% CI 1.01–4.30),
total cholesterol ≥ 240 mg/dL (OR 1.67, 95% CI 1.01–2.74),
glomerular filtration rate < 60 mL/min/1.73 m2 (OR 2.17,
95% CI 1.10–4.30), and non-Hispanic black ethnicity (OR
2.39, 95% CI 1.11–5.12). Overweight (body mass index
25–30 kg/m2) and obese individuals (body mass index
> 30 kg/m2) were less likely to have abnormal ankle-brachial
index, OR 0.87 and 0.54, respectively, compared with
normal weight individuals (referent), although body mass
index was not an independent determinant of abnormal
ankle-brachial index.
Risk factors for PAD in women were assessed in the
Heart and Estrogen/Progestin Replacement Study (Hsia
2000), a cohort of 2763 postmenopausal women with
coronary heart disease. Independent predictors of peripheral
arterial revascularization or amputation among women
assigned to placebo for 4.1 years included hypertension
(relative risk 2.66, 95% CI 1.60–4.44) and diabetes (relative
risk 1.98, 95% CI 1.27–3.11). Negative predictors in Cox
proportional hazards models included body mass index
(relative risk 0.70, 95% CI 0.56–0.88) and high-density lipo-
protein cholesterol (relative risk 0.76, 95% CI 0.60–0.96).
The relationship between chronic kidney disease and
PAD has been identified in both a random sample of
United States residents and in a cohort of women with
coronary heart disease (O’Hare, Glidden, et al 2004; O’Hare,
Vittinghoff, et al 2004). In the Heart and Estrogen/Progestin
Replacement Study, the rate of lower extremity re-
vascularization or amputation was inversely related to
creatinine clearance. After multivariate adjustment, the
relative risk among women with creatinine clearanceVascular Health and Risk Management 2005:1(2) 114
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30–59 mL/min/1.73 m
2 was 1.63 (95% CI 1.04–2.54)
compared with women with creatinine clearance ≥ 60 mL/
min/1.73 m
2 (referent). Among women with creatinine
clearance < 30 mL/min/1.73 m
2, relative risk was 3.24 (95%
CI 1.20–8.78) (O’Hare, Vittinghoff, et al 2004).
Treatment
Peripheral arterial disease is a marker of systemic
atherosclerosis; consequently, aggressive management of
conventional atherosclerotic risk factors should be
undertaken, especially smoking cessation. Exercise is also
an important component of clinical management in patients
with lower extremity arterial atherosclerosis (Menard 2004);
supervised exercise, even once weekly, appears to improve
long-term outcomes compared with exercise advice alone
(Cheetham 2004). Potential mechanisms underlying the
benefits of exercise training include improved oxygen
extraction and utilization, better walking biomechanics,
enhancement of collateral blood flow, favorable effects on
endothelial function, arterial compliance, free radical
formation, and inflammation (Stewart 2002; Falcone 2003).
Pharmacologic interventions can: (1) improve
claudication symptoms; (2) reduce cardiovascular events in
patients with PAD; or (3) reduce incident peripheral arterial
events in individuals with or without PAD at baseline.
Gender-specific data is generally not available, so these
agents are briefly summarized. The one therapeutic area
specifically studied in women is the role of postmenopausal
hormone therapy, which is discussed in more detail.
Lipid-lowering agents
A secondary analysis of the Scandinavian Simvastatin
Survival Study, a cohort of 4444 coronary heart disease
patients including 827 women, identified new or worsening
intermittent claudication in 2.3% of participants assigned
to simvastatin 40 mg daily compared with 3.6% of those
assigned to placebo during median follow up of 5.4 years, a
relative risk of 0.62 (95% CI 0.44–0.88) (Pederson 1998).
Both simvastatin (Aronow 2003; Mondillo 2003) and
atorvastatin (Mohler 2003) have been evaluated in patients
with claudication. In a group of 86 patients with claudication
and hypercholesterolemia randomized to simvastatin 40 mg
or placebo for 6 months, pain-free walking distance was
increased by simvastatin (+90 meters, 95% CI 64–116
meters, p < 0.005) (Mondillo 2003). In a trial of 354 patients
with claudication, including 81 women (23%) randomized
to atorvastatin 10 mg, atorvastatin 80 mg, or placebo for
12 months, pain-free walking time improved by 63%
(91 ± 15 seconds) in the atorvastatin 80 mg group compared
with 38% (39 ± 8 seconds) in the placebo group (p = 0.025)
(Mohler 2003). Although quality of life measures did not
differ among treatment groups, the combined atorvastatin
groups had significantly fewer clinical peripheral vascular
events (2 events in the atorvastatin 80 mg group, 1 in the
atorvastatin 10 mg group, 9 in the placebo group, p = 0.003).
Angiotensin-converting enzyme (ACE)
inhibitors
Ramipril reduced cardiovascular events in patients with
peripheral vascular disease in the Heart Outcomes
Prevention Evaluation trial, which randomized 9297 high-
risk patients (2480 women) to ramipril or placebo for 4.5
years (Yusuf 2000). Among women enrolled, 49.4% had
PAD at baseline defined as claudication, > 50% stenosis by
angiography, prior peripheral revascularization, or ankle-
brachial index < 0.9. In women, ramipril reduced the primary
end point (myocardial infarction, stroke, or cardiovascular
death) from 14.9% to 11.3% (relative risk 0.77, 95% CI
0.62–0.96) (Lonn 2002).
Antiplatelet agents
Aspirin, clopidogrel, and ticlopidine have all been
demonstrated to reduce cardiovascular events in patients
with PAD, but gender-specific analyses are lacking. In meta-
analysis of patients with PAD, aspirin reduced the OR for
major vascular events from 7.1% to 5.8% (p < 0.004)
(Antithrombotic Trialists’ Collaboration 2003).
The Clopidogrel versus Aspirin in Patients at Risk of
Ischemic Events trial randomized 19 185 patients with
cardiovascular disease, including 6452 with PAD at baseline,
to clopidogrel 75 mg daily or aspirin 325 mg daily for a mean
of 1.9 years (CAPRIE Steering Committee 1996). Among
those with PAD at study entry, the primary outcome (stroke,
myocardial infarction, or vascular death) was identified in
3.7% per year in the clopidogrel group vs 4.9% per year in
the aspirin group, an adjusted risk reduction of 23.8% (95%
CI 8.9%–36.2%).
Although ticlopidine has also been shown to reduce
coronary and cerebrovascular events in patients with
claudication (relative risk reduction 0.66, 95% CI 0.45–0.96)
(Janzon 1990), this agent is not widely used because of
gastrointestinal symptoms, neutropenia, and thrombotic
thrombocytopenic purpura.Vascular Health and Risk Management 2005:1(2) 115
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Postmenopausal hormone therapy
During the two years preceding menopause, women’s low-
density lipoprotein cholesterol rises by 10%, high-density
lipoprotein cholesterol falls by 6%, and triglycerides rise
by 11% (Jensen 1990). Until recently, postmenopausal
hormone therapy, which ameliorates these unfavorable lipid
changes (The Writing Group for the PEPI Trial 1995), was
believed to prevent atherosclerosis.
The association of postmenopausal hormone therapy
with ankle-brachial index was studied in a population-based
observational study of 2196 Dutch women, aged 55–80
years (Westendorp 2000). Recent postmenopausal hormone
use was reported by 31 women and remote use by 320
women. Duration of therapy ranged from 1 to more than 15
years; 9% of hormone users had taken progestin in addition
to estrogen. Ankle-brachial index < 0.9 was identified in 284
women (13%). In logistic regression analyses adjusted for
age, smoking, and education, women who reported using
postmenopausal hormones for at least one year were less
likely to have abnormal ankle-brachial index (relative risk
0.48, 95% CI 0.24–0.85) compared with never users
(referent). When short- and long-term hormone users were
combined, relative risk of abnormal ankle-brachial index
was 0.65 (95% CI 0.44–0.98).
Other observational studies found that women taking
postmenopausal estrogen had less severe carotid athero-
sclerosis, assessed by ultrasound (Jonas 1996; Le Gal 2003).
Recent randomized trials of postmenopausal hormone
therapy have underscored the limitations of observational
studies in evaluating the risks and benefits of estrogen.
Peripheral arterial disease has been less intensively studied
than coronary heart disease or stroke, but some data is
available from randomized trials.
In one randomized trial using an intermediate outcome
of change in intima-medial thickness assessed by ultrasound,
unopposed estradiol reduced progression of carotid disease
(Hodis 2001). Another trial, using combination estrogen
with progestin found no effect on progression of ultra-
sonographic carotid atherosclerosis (Byington 2002).
Three large randomized trials with clinical end points
have now assessed the impact of postmenopausal hormone
therapy on clinical cardiovascular end points, with PAD
as a prespecified secondary outcome. The Heart and
Estrogen/Progestin Replacement Study randomized 2763
women with documented coronary heart disease to
conjugated estrogens (6.25 mg daily) with continuous
medroxyprogesterone acetate (2.5 mg daily) or to placebo.
Peripheral arterial disease, assessed as peripheral arterial
revascularization or amputation, was a prespecified
secondary outcome. During 4.1 years of follow up, 143
lower extremity arterial events were identified, 77 among
women assigned to placebo, and 66 in women assigned to
conjugated estrogens with progestin (Hsia 2000). The
age-adjusted relative risk for lower extremity events
with combination hormone therapy was 0.88 (95% CI
0.58–1.35); multivariate-adjusted relative risk was 0.85
(95% CI 0.56–1.31).
For all types of PAD (aortic, carotid, and lower
extremity), the relative hazard with combination estrogen/
progestin was 0.87 (95% CI 0.66–1.44); the annual
incidence of peripheral arterial events was 2.9%.
Independent predictors of peripheral arterial events differed
in the two treatment groups; among placebo recipients,
hypertension and diabetes were positive determinants,
whereas high-density lipoprotein cholesterol and body mass
index were negative determinants of incident peripheral
arterial events. In contrast, among women assigned to
combination hormone therapy, diabetes and current smoking
were positive predictors of peripheral arterial events. The
observed potentiation by estrogen/progestin of the adverse
effects of smoking (p-value for interaction = 0.03) may
parallel the increased risk of myocardial infarction among
oral contraceptive users (Lewis 1996) and provides an
argument against prescribing postmenopausal hormones to
smokers.
In The Women’s Health Initiative Estrogen Plus
Progestin Trial, 16 608 generally healthy postmenopausal
women with intact uterus were randomly assigned to
conjugated estrogens (6.25 mg daily) with continuous
medroxyprogesterone acetate (2.5 mg daily) or to placebo
– the same regimen as the Heart and Estrogen/Progestin
Replacement Study. During 5.6 years of follow up, the
incidence of peripheral arterial events, defined as overnight
hospitalization for either peripheral arterial symptoms or
intervention, was low (0.14% per year), reflecting the overall
healthy condition of trial participants. The hazard ratio for
lower extremity events with combination estrogen/progestin
was 1.07 (95% CI 0.62–1.84) (Hsia 2004). For all peripheral
arterial events (including aortic and carotid disease), the
hazard ratio was 0.89 (95% CI 0.63–1.25). Subgroup
analysis did not identify any characteristics associated with
particularly high- or low-risk of PAD with combination
hormone therapy.
The Women’s Health Initiative Estrogen Alone Trial
randomized 10 739 women with prior hysterectomy withVascular Health and Risk Management 2005:1(2) 116
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conjugated estrogens (0.625 mg/daily) or to placebo (The
Women’s Health Initiative Steering Committee 2004).
Analyses of peripheral arterial events in that trial have not
yet been completed. The coronary risk with unopposed
estrogen (hazard ratio 0.91, 95% CI 0.75–1.12) appears to
differ from that with combination estrogen/progestin
(hazard ratio 1.24, nominal 95% CI 1.00–1.54) (Manson
2003). Whether the risk of peripheral arterial events with
unopposed estrogen differs from that with combination
estrogen/progestin remains to be seen.
Summary
Lower extremity PAD occurs with similar frequency in men
and women. Among women with abnormal ankle-brachial
index, 95% will not report claudication. Consequently, non-
invasive screening, such as measuring the ankle-brachial
index, is appropriate in asymptomatic individuals with
atherosclerotic risk factors. Clinical management of lower
extremity arterial disease should include physical training,
optimally with supervised exercise, and aggressive treatment
of conventional atherosclerotic risk factors. The increased
coronary and cerebrovascular risk in individuals with PAD
appears to be attenuated by ACE inhibition and clopidogrel.
Postmenopausal hormone therapy with combination
estrogen/progestin provides no protection against peripheral
arterial events. The role of unopposed estrogen for
prevention of PAD remains to be determined.
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